Home - National Multiple Sclerosis Society

Skip to navigation Skip to content
National MS Society

Email not displaying correctly? View it in your browser.
eNews May 2011 - National MS Society
Positive Reports from Two Phase III Trials

BG-12 and laquinimod backed by promising data

In a recent press release, Biogen Idec reported that their oral MS disease-modifier, BG-12, significantly reduced the number of people with MS who had relapses during a two-year study of more than 1,200 people with MS. At the annual meeting of the American Academy of Neurology in April, Teva Pharmaceuticals reported that their oral MS therapy, laquinimod, reduced the relapse rate in those taking the drug in a study of 1,106 people with MS. Both companies are awaiting the results of other phase III trials involving these therapies before submitting applications to the FDA.

More on BG-12

Laquinimod at AAN

 Find us on Facebook 

YouTube MySpace Twitter

eNews Meet Heading


Angela Hahn

Angela Hahn’s research is personal
Save the Date


eNews World MS Day 05-11

May 25 is World MS Day. Join the global movement and share what MS= to you.

Facts on Vitamin DWant the Facts on Vitamin D? 

Read the latest on vitamin D research, progressive MS, getting back into the workforce and more: The Summer issue of Momentum is now LIVE online in our new fully interactive digital edition. Comment on stories and on other readers’ comments, download pages as PDFs, share stories via e-mail or social media. Read on laptop, iPhone, iPad, Android or an e-reader with Internet connection.

Get Momentum now


eNews Teaser 3 05-11 Every dollar gets doubled

Thanks to a generous gift from Pure Protein®, national sponsor and maker of high-quality protein bars, your donation will be immediately matched and put to work moving us closer to a world free of MS. For a limited time only, your donation will be matched dollar for dollar.

Donate Now

More MS News 

May 3: Study of oral teriflunomide and interferon beta recruiting people with relapsing forms of MS worldwide

April 26: Recent mouse studies may provide new targets to stop MS

Read more about these and other recent reports

This communication is partially sponsored through the generous support of Biogen Idec;
EMD Serono and Pfizer, Inc; Novartis Pharmaceuticals Corporation; and Teva Neuroscience, Inc.

MS Active Source  MS LifeLinesNovartis Teva Neuroscience

Join a Walk MS Event       Join a Bike MS Event      Shop at the Society Store

National MS Society | View as Web page | Subscribe | Legal Notice/Privacy Policy | Email Preferences | Unsubscribe

MS stops people from moving. The National MS Society exists to make sure it doesn’t. We are a collective of passionate individuals, moving together to create a world free of MS.

Please do not reply to this email as we are unable to quickly respond to messages sent to this address. To receive information about living with MS, Bike MS or Walk MS — or to contact National MS Society staff in your area — please
visit our Web site.

Early and ongoing treatment with an FDA-approved therapy can make a difference for people with multiple sclerosis. Learn about your options by talking to your health care professional and contacting the National MS Society at http://www.nationalmssociety.org/ or 1-800-344-4867.

National Multiple Sclerosis Society | 733 Third Avenue | New York, NY | 10017

This message was sent to  .
To ensure that you continue to receive our emails, please add us to your address book.